首页> 外文OA文献 >Cellular RNA Targeting by Platinum (II) Anticancer Therapeutics
【2h】

Cellular RNA Targeting by Platinum (II) Anticancer Therapeutics

机译:铂(II)抗癌药物靶向细胞RNA

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cis-diamminedichloroplatinum (II), or cisplatin, is a widely prescribed anticancer compound, currently one of only three platinum (II) complexes FDA approved for cancer treatment. Despite its widespread use, we lack a comprehensive picture of global drug targets, which would lend valuable insights into the molecular mechanisms of action and resistance in different tissues. Drug binding to genomic DNA is an accepted cause of downstream apoptotic signaling, but less than 10% of Pt (in the case of cisplatin) accumulates within genomic DNA. Non-genomic contributions to cisplatin's therapeutic action are also under active investigation. In particular, cisplatin treatment can disrupt RNA-based processes such as splicing and translation. Pt(II) targeting of non-DNA species such as RNA may contribute to or sensitize a cell to the downstream effects of this drug, including the induction of apoptosis. Chapter I summarizes the activity profile of Pt(II) therapeutics, describing cellular uptake, cellular localization, incidences of Pt(II) accumulation within RNA, and RNA processes affected following drug treatment. Chapter II reports our thorough investigation of the distribution of Pt species throughout messenger and ribosomal RNA, with the discovery that Saccharomyces cerevisiae ribosomes act as a de facto cellular Pt sponge. In Chapter III, we report the synthesis of an azide-functionalized platinum (II) species, picazoplatin, for post-treatment click labeling and isolation of drug targets in vivo. Picazoplatin was designed to circumvent mislocalization and misprocessing of Pt typically encountered when trying to track small molecules tethered to large, charged fluorophores. This chapter contains several proof-of-principle studies validating the use of this class of reagents for future purification and sequencing of Pt-bound nucleic acids. Chapter IV describes the first application of the click-capable Pt reagent technology: the demonstration of significant in-gel fluorescent detection of Pt-bound ribosomal RNA and transfer RNA extracted from picazoplatin-treated S. cerevisiae and the first evidence that cellular tRNA is a platinum substrate. Chapter V summarizes these data, which suggest a potential ribotoxic mechanism for cisplatin cytotoxicity and broadly describe a convenient click chemistry methodology that can be applied to identify other metal or covalent modification-based drug targets.This dissertation includes previously published and unpublished co-authored material.
机译:顺二氨二氯铂(II)或顺铂是一种广泛使用的抗癌化合物,目前是FDA批准用于癌症治疗的仅有的三种铂(II)配合物之一。尽管已被广泛使用,但我们缺乏有关全球药物靶标的全面介绍,这将使我们对不同组织中的作用和耐药性分子机制产生宝贵的见解。药物与基因组DNA的结合是下游凋亡信号转导的公认原因,但在基因组DNA内累积的Pt少于10%(在顺铂的情况下)。对顺铂治疗作用的非基因组贡献也正在积极研究中。特别是,顺铂处理可以破坏基于RNA的过程,例如剪接和翻译。靶向非DNA物种(例如RNA)的Pt(II)可能有助于或使细胞对该药物的下游效应敏感,包括诱导细胞凋亡。第一章总结了Pt(II)治疗药物的活性概况,描述了细胞吸收,细胞定位,RNA中Pt(II)积累的发生率以及药物治疗后受影响的RNA过程。第二章报告了我们对整个信使和核糖体RNA中Pt物种分布的深入研究,并发现酿酒酵母核糖体可作为事实上的细胞Pt海绵。在第三章中,我们报告了叠氮化物官能化铂(II)物种吡唑并铂的合成,用于后处理点击标记和体内药物靶标的分离。 Picazoplatin的设计可避免试图追踪拴在大的带电荧光团上的小分子时通常遇到的Pt的错误定位和错误处理。本章包含若干原理验证研究,验证了此类试剂在将来与Pt结合的核酸的纯化和测序中的用途。第四章介绍了可点击的Pt试剂技术的首次应用:显着凝胶内荧光检测Pt结合的核糖体RNA和从吡唑并铂处理的酿酒酵母提取的转移RNA的演示,并首次证明了细胞tRNA是一种铂基板。第五章总结了这些数据,这些数据提示了顺铂细胞毒性的潜在核毒性机制,并广泛描述了一种方便的点击化学方法,可用于鉴定其他基于金属或共价修饰的药物靶标。本文包括以前发表的和未发表的合着材料。

著录项

  • 作者

    Osborn Maire;

  • 作者单位
  • 年度 2014
  • 总页数
  • 原文格式 PDF
  • 正文语种 en_US
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号